(BFM Bourse) – The Montpellier biotech has received an agreement to issue a patent in the United States protecting, for 20 years, the property of NanoManganese, its drug candidate intended for the treatment of large irradiated populations after a civil or military nuclear accident.
Medesis Pharma announces good news for NanoManganese. The biotech located in Baillargues announces that it has received a “Notice of Allowance”, i.e. an agreement for the registration in the United States of its patent protecting the property of its radiation protection drug candidate for 20 years.
Founded by Dr. Jean-Claude Morel, Medesis Pharma is developing a proprietary oral administration technology (Aonys). It was used to develop NanoManganese, its drug candidate intended to treat irradiated populations, either internally or externally, after a military or civilian (medical or industrial) nuclear accident, against which there is currently no suitable treatment. .
This treatment is administered after (decreasing period of an abnormal state, editor’s note) or in the minutes or hours following overexposure to ionizing radiation.
Other patents pending
Medesis Pharma indicates that it has conducted, in collaboration with the Armed Forces Biomedical Research Institute, studies on irradiated animals. The company was able to observe “very favorable results” allowing survival of all animals during irradiation at an LD50 dose (after which 50% of animals die within 10 days). “A very important element in radiation protection, the activity is observed in radiomitigation, that is to say effective when the administration takes place within 24 hours following irradiation”, specifies Medesis Pharma.
The company reports that it has entrusted the company Freemind Group with the search for funding from the US government in order to finalize the development of this product. At the same time, the company adds that this patent is in the process of being registered in other countries or geographical areas including Europe, Canada, Japan, China, or Eurasia.
The company is also developing two other drug candidates, NU01 and NU02, also aimed at treating contaminated or irradiated populations after a military or civilian nuclear accident.
On the Paris Stock Exchange, the title of the biotech located in Baillargues only gleans more than 0.7% to 1.365 euro Tuesday, around 2:30 p.m. The action had gained up to 18.4% from the first negotiations on the Paris Stock Exchange, after the announcement of the day.
A favorable report for NanoLithium
Medesis Pharma therefore adds a new success to its development. At the end of May, the company had obtained the green light from the experts of the Independent Clinical Data Safety Monitoring Committee on its phase 2 clinical study (intermediate stage of clinical trials) for NanoLithium, its experimental treatment in Alzheimer’s disease.
This decision was made following an initial interim review of the safety data which covered 35 patients treated for at least one month on the date the database was established. After reviewing the data, experts from the IDSMB (a group of independent scientific experts who advise US medical authorities) concluded that no serious side effects were observed, that there were no there was no safety signal and they recommend continuing the trial as planned.
The complete results of the first phase – which establishes a clinical report on behavioral and psychological disorders, after three months of double-blind treatment versus placebo – are expected at the end of 2023. According to Medesis Pharma, the results of the end of the full study on its experimental treatment in Alzheimer’s disease, could take place in the 3rd quarter of 2024.
Sabrina Sadgui – ©2023 BFM Bourse
Are you following this action?
Receive all the information about MEDESIS PHARMA in real time: